Multivalent antibodies: when design surpasses evolution
dc.contributor.author | Cuesta Martínez, Ángel | |
dc.contributor.author | Sainz-Pastor, Noelia | |
dc.contributor.author | Bonet, Jaume | |
dc.contributor.author | Oliva, Baldomero | |
dc.contributor.author | Álvarez-Vallina, Luis | |
dc.date.accessioned | 2024-01-12T13:07:48Z | |
dc.date.available | 2024-01-12T13:07:48Z | |
dc.date.issued | 2010 | |
dc.description.abstract | Evolutionary pressure has selected antibodies as key immune molecules acting against foreign pathogens. The development of monoclonal antibody technology has allowed their widespread use in research, real-time diagnosis and treatment of multiple diseases, including cancer. However, compared with hematologic malignancies, solid tumors have often proven to be relatively resistant to antibody-based therapies. In an attempt to improve the tumor-targeting efficacy of antibodies, new formats with modified, multivalent properties have been generated. Initially, these formats imitated the structure of native IgG, creating mostly monospecific, bivalent antibodies. Recently, novel trivalent antibodies have been developed to maximize tumor targeting capabilities through enhanced biodistribution and functional affinity. We review recent advances in the engineering of multivalent antibodies and further discuss their promise as agents for invivo diagnostics and therapy. | |
dc.description.department | Depto. de Bioquímica y Biología Molecular | |
dc.description.faculty | Fac. de Farmacia | |
dc.description.refereed | TRUE | |
dc.description.sponsorship | Ministerio de Ciencia e Innovación (España) | |
dc.description.sponsorship | Comunidad de Madrid | |
dc.description.sponsorship | European Commission | |
dc.description.status | pub | |
dc.identifier.citation | Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010;28(7):355-362. doi:10.1016/j.tibtech.2010.03.007 | |
dc.identifier.doi | 10.1016/j.tibtech.2010.03.007 | |
dc.identifier.essn | 1879-3096 | |
dc.identifier.issn | 0167-7799 | |
dc.identifier.officialurl | https://doi.org/10.1016/j.tibtech.2010.03.007 | |
dc.identifier.relatedurl | https://www.sciencedirect.com/science/article/pii/S0167779910000557?via%3Dihub | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/92799 | |
dc.issue.number | 7 | |
dc.journal.title | Trends in Biotechnology | |
dc.language.iso | eng | |
dc.page.final | 362 | |
dc.page.initial | 355 | |
dc.publisher | Cell Press | |
dc.relation.projectID | info:eu-repo/grantAgreement/BIO2008-03233 | |
dc.relation.projectID | info:eu-repo/grantAgreement/Angiobodies-S-BIO-0236-2006 | |
dc.relation.projectID | info:eu-repo/grantAgreement/BIO2008-00205 | |
dc.rights.accessRights | restricted access | |
dc.subject.cdu | 612.017 | |
dc.subject.ucm | Ciencias Biomédicas | |
dc.subject.unesco | 24 Ciencias de la Vida | |
dc.title | Multivalent antibodies: when design surpasses evolution | |
dc.type | journal article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 28 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 963e050e-5a67-40d7-8e25-3dc7ff5a8619 | |
relation.isAuthorOfPublication.latestForDiscovery | 963e050e-5a67-40d7-8e25-3dc7ff5a8619 |
Download
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Multivalent_antibodies.pdf
- Size:
- 439.85 KB
- Format:
- Adobe Portable Document Format